News Poxel taking two shots at NASH as pharma waits on FDA's OCA ... Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NA
News Trial sets up 2020 filing for Poxel's novel diabetes drug French biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 diabetes, setting up a first filing in Japan next year.
News Ramaswamy's Roivant signs diabetes drug deal with Poxel Biotech entrepreneur hopes to bounce back from Alzheimer's disappointment
News Latigo raises $150m for non-opioid painkiller push Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl